United Therapeutics Sees Unusually High Options Volume (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) was the target of some unusual options trading activity on Wednesday. Investors acquired 4,930 call options on the company. This is an increase of approximately 241% compared to the average daily volume of 1,447 call options.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on UTHR shares. UBS Group reissued a “buy” rating on shares of United Therapeutics in a report on Tuesday, February 17th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research note on Thursday. Bank of America restated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday. HC Wainwright raised their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $533.55.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Price Performance

UTHR opened at $503.60 on Friday. The business has a 50 day moving average price of $484.64 and a two-hundred day moving average price of $444.51. The company has a market capitalization of $21.69 billion, a price-to-earnings ratio of 18.05, a price-to-earnings-growth ratio of 2.85 and a beta of 0.85. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $537.19.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Equities analysts expect that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total value of $520,000.00. Following the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,178,800. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $476.34, for a total value of $3,953,622.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,520,261.54. This trade represents a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 407,954 shares of company stock worth $197,601,528 over the last quarter. 10.30% of the stock is owned by company insiders.

Institutional Trading of United Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its position in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. Wellington Management Group LLP raised its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC lifted its stake in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.